Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

13.83
+1.209.50%
Post-market: 13.81-0.0217-0.16%19:39 EDT
Volume:3.68M
Turnover:50.61M
Market Cap:1.09B
PE:6.81
High:14.19
Open:13.09
Low:13.01
Close:12.63
52wk High:17.29
52wk Low:5.70
Shares:78.65M
Float Shares:70.64M
Volume Ratio:2.42
T/O Rate:5.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.03
EPS(LYR):1.87
ROE:82.56%
ROA:2.29%
PB:4.69
PE(LYR):7.40

Loading ...

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

GlobeNewswire
·
May 07

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

GlobeNewswire
·
May 07

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

GlobeNewswire
·
May 07

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

GlobeNewswire
·
May 07

PagerDuty announces annual shareholder meeting

Reuters
·
May 05

California Public Utilities Commission Issues Decision in California Water Service’s 2024 General Rate Case, Infrastructure Improvement Plan

GlobeNewswire
·
May 01

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis

GlobeNewswire
·
Apr 30

Incyte Exceeds Q1 Expectations Driven by Strong Demand for Core Cancer Therapies

Deep News
·
Apr 28

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

GlobeNewswire
·
Apr 28

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

GlobeNewswire
·
Apr 28

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

GlobeNewswire
·
Apr 27

PagerDuty rumor highlighted in Betaville blog

TIPRANKS
·
Apr 24

Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

GlobeNewswire
·
Apr 24

Buy Rating on MiNK Therapeutics Driven by Promising Phase 2 Survival Benefit and Immune Activation in PD-1–Refractory Gastric Cancer

TIPRANKS
·
Apr 23

Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026

GlobeNewswire
·
Apr 23

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies

GlobeNewswire
·
Apr 21

LEADS BIOLABS-B (09887): First Patient Enrolled in Phase II Trial of LBL-024 for Front-Line Gastric or Gastroesophageal Junction Adenocarcinoma

Stock News
·
Apr 21

Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026

GlobeNewswire
·
Apr 21

Bayer’s AskBio to supply commercial-scale drug product for Regenerate-PD

TIPRANKS
·
Apr 20

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

GlobeNewswire
·
Apr 20